Figures & data
Figure 1 PANSS responders (defined by PANSS total score reduction thresholds of 20–50%) with AL 441 mg, 882 mg, or AL doses pooled: NNT and 95% CI vs placebo, at endpoint.
Note: *Upper bound 95% CI is 216.
Abbreviations: AL, aripiprazole lauroxil; CI, confidence interval; NNT, number needed to treat; ns, not significant at the P<0.05 threshold; PANSS, Positive and Negative Syndrome Scale.
Abbreviations: AL, aripiprazole lauroxil; CI, confidence interval; NNT, number needed to treat; ns, not significant at the P<0.05 threshold; PANSS, Positive and Negative Syndrome Scale.
Figure 2 PANSS responders (≥30% reduction from baseline PANSS total score) by study day with AL doses pooled: NNT and 95% CI vs placebo by days on therapy.
Abbreviations: AL, aripiprazole lauroxil; CI, confidence interval; NNT, number needed to treat; ns, not significant at the P<0.05 threshold; PANSS, Positive and Negative Syndrome Scale.
Table 1 PANSS total score: change from baseline* and Cohen’s d for AL vs placebo (LOCF)
Table 2 Rates and NNT vs placebo for study completion and NNH vs placebo for AE-related discontinuation (safety population)
Table 3 AE rates (Incidence ≥2% in any treatment arm) and NNH vs placebo (safety population)